Literature DB >> 8994424

Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia. Comparison of acetylcholine and substance P.

A A Quyyumi1, D Mulcahy, N P Andrews, S Husain, J A Panza, R O Cannon.   

Abstract

BACKGROUND: Whether the abnormal responses of the human coronary circulation to acetylcholine in patients with hypertension and hypercholesterolemia extend to other, nonmuscarinic stimulators of the endothelium and whether this signifies a specific abnormality of NO is not known. METHODS AND
RESULTS: We studied 26 patients with angiographically normal coronary arteries, 10 without risk factors, and 16 with either hypertension (n = 9) and/or hypercholesterolemia (n = 10). Dose-response curves were performed with acetylcholine, substance P, and sodium nitroprusside before and after NG-monomethyl-L-arginine (L-NMMA). Substance P produced predominantly epicardial coronary dilation, whereas the dilating effect of acetylcholine was mainly microvascular. There was no correlation between the responses to the two drugs. L-NMMA did not affect the response to sodium nitroprusside, but it suppressed dilation in response to both substance P and acetylcholine, suggesting that the latter promote bioavailability of NO from the coronary vascular endothelium. Compared with patients without risks, those with hypercholesterolemia and hypertension had significantly reduced vasodilation with substance P: 21% versus 12.6% (P = .004) increase in epicardial coronary diameter and 35% versus 19% (P < .05) decrease in vascular resistance. Similar differences were noted with acetylcholine but not with sodium nitroprusside or adenosine. Epicardial and microvascular dilations with substance P or acetylcholine after L-NMMA were similar in patients with and without risk factors, indicating that the reduced effect of endothelium-dependent vasodilators in those with hypertension and hypercholesterolemia is due to diminished NO activity.
CONCLUSIONS: (1) Substance P- and acetylcholine-induced coronary vasodilation, like that to acetylcholine, is at least partly due to stimulation of NO activity, indicating that the dysfunction of the coronary vascular endothelial cell layer is not restricted to muscarinic receptors. (2) Hypertension and hypercholesterolemia are associated with depression of both basal and pharmacologically stimulated bioavailability of NO.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8994424     DOI: 10.1161/01.cir.95.1.104

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  21 in total

1.  Regulation of the coronary vasomotor tone: What we know and where we need to go.

Authors:  E Toyota; R Koshida; N Hattan; W M Chilian
Journal:  J Nucl Cardiol       Date:  2001 Sep-Oct       Impact factor: 5.952

Review 2.  Invasive assessment of the coronary circulation: intravascular ultrasound and Doppler.

Authors:  David E Newby; Keith A A Fox
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

3.  Epigenetic upregulation of p66shc mediates low-density lipoprotein cholesterol-induced endothelial cell dysfunction.

Authors:  Young-Rae Kim; Cuk-Seong Kim; Asma Naqvi; Ajay Kumar; Santosh Kumar; Timothy A Hoffman; Kaikobad Irani
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-06-01       Impact factor: 4.733

4.  Plasma detection of NO by a catheter.

Authors:  Masami Goto; Seiichi Mochizuki
Journal:  Med Biol Eng Comput       Date:  2008-05       Impact factor: 2.602

Review 5.  Regulation of Coronary Blood Flow.

Authors:  Adam G Goodwill; Gregory M Dick; Alexander M Kiel; Johnathan D Tune
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

Review 6.  Is reversal of endothelial dysfunction still an attractive target in modern cardiology?

Authors:  Ify Mordi; Nikolaos Tzemos
Journal:  World J Cardiol       Date:  2014-08-26

Review 7.  The L-arginine-nitric oxide pathway in hypertension.

Authors:  Malte Kelm
Journal:  Curr Hypertens Rep       Date:  2003-02       Impact factor: 5.369

Review 8.  Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management.

Authors:  R Preston Mason
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 9.  [Right ventricle in arterial hypertension].

Authors:  W Motz
Journal:  Internist (Berl)       Date:  2004-10       Impact factor: 0.743

10.  Evidence for agonist-specific endothelial vasodilator dysfunction with ageing in healthy humans.

Authors:  Christopher A DeSouza; Christopher M Clevenger; Jared J Greiner; Derek T Smith; Greta L Hoetzer; Linda F Shapiro; Brian L Stauffer
Journal:  J Physiol       Date:  2002-07-01       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.